Revolution Medicines Prices New Pancreatic Cancer Drug at $39,800 per Month
Revolution Medicines received FDA approval for Rasonque, a once-daily oral treatment for metastatic pancreatic adenocarcinoma. The drug is priced with a wholesale acquisition cost of $39,800 for a 30-day supply, totaling up to $477,600 annually before discounts or assistance programs. The approval was based on the RASolute 302 trial showing significant improvements in survival and response rates compared to chemotherapy. However, concerns remain about patient access due to high costs and potential prior-authorization hurdles from insurers. The drug does not require a companion diagnostic test for tumor mutations, which may ease adoption. Revolution Medicines must now prove physician uptake and payer coverage during its commercial launch. While the clinical results are strong, long-term success will depend on expanding Rasonque’s use to earlier treatment settings through further trials.
Tickers: $RVMD